Covered recipient · General Payments record
SHELLY SENDERS
Allopathic & Osteopathic Physicians Pediatrics
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$20.00
1 record · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Gift | $20.00 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $20.00 | 1 |
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SHELLY SENDERS
NPI 1629030242 · CMS profile ID 72774
Allopathic & Osteopathic Physicians / Pediatrics
SOUTH EUCLID, OH
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1629030242?year=2021&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SHELLY SENDERS, NPI 1629030242, CMS profile ID 72774. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1629030242?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). SHELLY SENDERS, NPI 1629030242, CMS profile ID 72774. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1629030242?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- SHELLY SENDERS, NPI 1629030242, CMS profile ID 72774, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1629030242?year=2021&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
1 matching record · $20.00 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–1 of 1.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| PFIZER INC. | $20.00 | 06/04/2021 | Gift | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833593479 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2021, 2024
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2021 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $54,019.97 | 12 |
| PY2025 | Principal investigator | $1,902,218.36 | 170 |
| PY2024 | Recipient | $275,103.88 | 9 |
| PY2024 | Principal investigator | $1,504,720.66 | 124 |
| PY2023 | Recipient | $102,576.00 | 31 |
| PY2023 | Principal investigator | $2,132,839.28 | 106 |
| PY2022 | Recipient | $295,641.25 | 8 |
| PY2022 | Principal investigator | $2,774,710.46 | 131 |
| PY2021 | Recipient | $6,400.00 | 2 |
| PY2021 | Principal investigator | $3,331,898.39 | 191 |
| PY2020 | Recipient | $940.00 | 1 |
| PY2020 | Principal investigator | $1,688,992.60 | 356 |
| PY2019 | Principal investigator | $803,780.84 | 320 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
133 records in PY2024
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $8,762.56 | 12/31/2024 | Non-covered Recipient Entity Senders Pediatrics | A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants | No dispute reported | 06/30/2026 | 1136404476 |
| Principal investigator 1 | PFIZER INC. | $14,959.29 | 12/31/2024 | Non-covered Recipient Entity Dr Shelly Senders | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 1130969689 |
| Principal investigator 1 | PFIZER INC. | $5,435.10 | 12/31/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD | A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE | No dispute reported | 06/30/2026 | 1130971605 |
| Principal investigator 1 | PFIZER INC. | $2,072.72 | 12/31/2024 | Non-covered Recipient Entity Dr Shelly Senders | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130971610 |
| Principal investigator 1 | PFIZER INC. | $8,698.85 | 12/20/2024 | Non-covered Recipient Entity Dr Shelly Senders | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 1130968433 |
| Principal investigator 1 | PFIZER INC. | $920.40 | 12/20/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD INC | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | No dispute reported | 06/30/2026 | 1130969001 |
| Principal investigator 1 | PFIZER INC. | $922.77 | 12/20/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD | A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE | No dispute reported | 06/30/2026 | 1130969683 |
| Recipient | ModernaTX, Inc. | $3,142.62 | 12/19/2024 | Covered Recipient Physician | A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease | No dispute reported | 06/30/2026 | 1147190727 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,009.13 | 12/18/2024 | Non-covered Recipient Entity Dr Shelly David Senders Md Inc | Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) | No dispute reported | 06/30/2026 | 1128730672 |
| Principal investigator 1 | ModernaTX, Inc. | $22,691.44 | 12/13/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147185065 |
| Principal investigator 1 | PFIZER INC. | $25,342.14 | 12/11/2024 | Non-covered Recipient Entity Dr Shelly Senders | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 1130968439 |
| Principal investigator 1 | PFIZER INC. | $3,627.26 | 12/05/2024 | Non-covered Recipient Entity Dr Shelly Senders | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130968427 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,600.00 | 12/04/2024 | Non-covered Recipient Entity Dr Shelly David Senders Md Inc | Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) | No dispute reported | 06/30/2026 | 1128730674 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $14,019.57 | 12/02/2024 | Non-covered Recipient Entity Dr Shelly David Senders Md Inc | Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) | No dispute reported | 06/30/2026 | 1128730676 |
| Principal investigator 1 | PFIZER INC. | $1,227.20 | 11/26/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD INC | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | No dispute reported | 06/30/2026 | 1130988005 |
| Principal investigator 1 | ModernaTX, Inc. | $45,609.39 | 11/22/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147185063 |
| Principal investigator 1 | PFIZER INC. | $6,591.17 | 11/22/2024 | Non-covered Recipient Entity Dr Shelly Senders | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 1130988162 |
| Principal investigator 1 | ModernaTX, Inc. | $44,185.44 | 10/25/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147185061 |
| Principal investigator 1 | PFIZER INC. | $9,778.86 | 10/23/2024 | Non-covered Recipient Entity Dr Shelly Senders | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130994023 |
| Principal investigator 1 | PFIZER INC. | $1,053.00 | 10/16/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD INC | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | No dispute reported | 06/30/2026 | 1130994028 |
| Principal investigator 1 | PFIZER INC. | $3,259.62 | 10/16/2024 | Non-covered Recipient Entity Dr Shelly Senders | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130994177 |
| Principal investigator 1 | PFIZER INC. | $9,721.39 | 10/16/2024 | Non-covered Recipient Entity Dr Shelly Senders | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 1130994457 |
| Principal investigator 1 | PFIZER INC. | $2,717.55 | 10/16/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD | A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE | No dispute reported | 06/30/2026 | 1130994738 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $86,333.43 | 10/16/2024 | Non-covered Recipient Entity Dr Shelly David Senders Md Inc | Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) | No dispute reported | 06/30/2026 | 1128730678 |
| Principal investigator 1 | PFIZER INC. | $3,813.16 | 10/09/2024 | Non-covered Recipient Entity Dr Shelly Senders | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130993884 |
| Principal investigator 1 | PFIZER INC. | $5,026.06 | 10/09/2024 | Non-covered Recipient Entity Dr Shelly Senders | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 1130994183 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $344.02 | 10/07/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD INC | A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1127537630 |
| Principal investigator 1 | PFIZER INC. | $29,601.39 | 10/05/2024 | Non-covered Recipient Entity Dr Shelly Senders | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130993872 |
| Principal investigator 1 | PFIZER INC. | $746.20 | 10/05/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD INC | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | No dispute reported | 06/30/2026 | 1130994172 |
| Principal investigator 1 | PFIZER INC. | $1,297.40 | 10/03/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD INC | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | No dispute reported | 06/30/2026 | 1130994017 |
| Principal investigator 1 | PFIZER INC. | $33,152.21 | 10/03/2024 | Non-covered Recipient Entity Dr Shelly Senders | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130994733 |
| Principal investigator 1 | PFIZER INC. | $7,539.09 | 10/02/2024 | Non-covered Recipient Entity Dr Shelly Senders | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 1130993878 |
| Principal investigator 1 | PFIZER INC. | $11,617.23 | 10/01/2024 | Non-covered Recipient Entity Dr Shelly Senders | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 1130994451 |
| Principal investigator 1 | ModernaTX, Inc. | $31,189.53 | 09/25/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147185059 |
| Recipient | ModernaTX, Inc. | $4,570.15 | 09/25/2024 | Covered Recipient Physician | A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease | No dispute reported | 06/30/2026 | 1147190725 |
| Principal investigator 1 | PFIZER INC. | $4,388.80 | 09/25/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD INC | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | No dispute reported | 06/30/2026 | 1131013716 |
| Principal investigator 1 | PFIZER INC. | $25,065.15 | 09/19/2024 | Non-covered Recipient Entity Dr Shelly Senders | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 1131013729 |
| Recipient | ModernaTX, Inc. | $24,002.26 | 09/18/2024 | Covered Recipient Physician | A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease | No dispute reported | 06/30/2026 | 1147190723 |
| Principal investigator 1 | PFIZER INC. | $2,545.40 | 09/18/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD INC | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | No dispute reported | 06/30/2026 | 1131013132 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $662.54 | 09/11/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD INC | A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1127537612 |
| Principal investigator 1 | PFIZER INC. | $3,335.80 | 09/10/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD INC | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | No dispute reported | 06/30/2026 | 1131013116 |
| Principal investigator 1 | PFIZER INC. | $1,554.54 | 09/04/2024 | Non-covered Recipient Entity Dr Shelly Senders | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131013127 |
| Principal investigator 1 | PFIZER INC. | $1,601.60 | 09/04/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD INC | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | No dispute reported | 06/30/2026 | 1131013722 |
| Principal investigator 1 | PFIZER INC. | $3,159.26 | 08/27/2024 | Non-covered Recipient Entity Dr Shelly Senders | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131029037 |
| Principal investigator 1 | ModernaTX, Inc. | $51,855.11 | 08/23/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147185035 |
| Principal investigator 1 | PFIZER INC. | $13,000.00 | 08/23/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD | A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE | No dispute reported | 06/30/2026 | 1131028454 |
| Principal investigator 1 | PFIZER INC. | $10,181.30 | 08/23/2024 | Non-covered Recipient Entity Dr Shelly Senders | AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131029032 |
| Principal investigator 1 | PFIZER INC. | $10,298.60 | 08/16/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD INC | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | No dispute reported | 06/30/2026 | 1131028460 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $194.59 | 08/14/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD INC | A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1127537620 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,872.00 | 08/14/2024 | Non-covered Recipient Entity Dr Shelly David Senders Md Inc | A Multi-center, Multi-national, Prospective Surveillance Study of Respiratory Syncytial Virus Disease in Infants and Toddlers 6 to < 22 Months of Age | No dispute reported | 06/30/2026 | 1128730656 |
| Principal investigator 1 | ModernaTX, Inc. | $37,826.10 | 08/07/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147185033 |
| Principal investigator 1 | PFIZER INC. | $6,519.24 | 07/31/2024 | Non-covered Recipient Entity Dr Shelly Senders | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131042718 |
| Recipient | ModernaTX, Inc. | $11,926.44 | 07/29/2024 | Covered Recipient Physician | A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease | No dispute reported | 06/30/2026 | 1147190715 |
| Principal investigator 1 | PFIZER INC. | $9,907.17 | 07/27/2024 | Non-covered Recipient Entity Dr Shelly Senders | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131042712 |
| Principal investigator 1 | ModernaTX, Inc. | $132.48 | 07/26/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD | A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease | No dispute reported | 06/30/2026 | 1147185071 |
| Principal investigator 1 | PFIZER INC. | $1,086.54 | 07/26/2024 | Non-covered Recipient Entity Dr Shelly Senders | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131044367 |
| Principal investigator 1 | ModernaTX, Inc. | $40.86 | 07/25/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD | A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease | No dispute reported | 06/30/2026 | 1147185069 |
| Principal investigator 1 | PFIZER INC. | $746.20 | 07/25/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD INC | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | No dispute reported | 06/30/2026 | 1131042822 |
| Recipient | Novavax Inc | $9,874.00 | 07/23/2024 | Covered Recipient Physician | A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years with a Pediatric Expansion in Adolescents (12 to younger than 18 Years) | No dispute reported | 06/30/2026 | 1123373928 |
| Principal investigator 1 | ModernaTX, Inc. | $17,865.83 | 07/19/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147185003 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $53,852.76 | 07/19/2024 | Non-covered Recipient Entity Dr Shelly David Senders Md Inc | Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) | No dispute reported | 06/30/2026 | 1128730646 |
| Principal investigator 1 | PFIZER INC. | $1,706.40 | 07/18/2024 | Non-covered Recipient Entity Senders Pediatrics | A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE | No dispute reported | 06/30/2026 | 1130917523 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $848.87 | 07/12/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD INC | A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1127537698 |
| Principal investigator 1 | PFIZER INC. | $44,414.89 | 07/11/2024 | Non-covered Recipient Entity Dr Shelly Senders | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131042706 |
| Principal investigator 1 | PFIZER INC. | $4,196.40 | 07/11/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD INC | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | No dispute reported | 06/30/2026 | 1131042811 |
| Principal investigator 1 | PFIZER INC. | $39,804.70 | 07/06/2024 | Non-covered Recipient Entity Dr Shelly Senders | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131044468 |
| Principal investigator 1 | PFIZER INC. | $1,279.80 | 07/03/2024 | Non-covered Recipient Entity Senders Pediatrics | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 1130917723 |
| Principal investigator 1 | PFIZER INC. | $5,103.80 | 07/03/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD INC | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | No dispute reported | 06/30/2026 | 1131042817 |
| Principal investigator 1 | PFIZER INC. | $24,174.80 | 06/29/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD INC | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | No dispute reported | 06/30/2026 | 1131069974 |
| Recipient | ModernaTX, Inc. | $122,225.62 | 06/27/2024 | Covered Recipient Physician | A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease | No dispute reported | 06/30/2026 | 1147190721 |
| Principal investigator 1 | ModernaTX, Inc. | $39,172.96 | 06/26/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147184805 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $351.48 | 06/14/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD INC | A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T | No dispute reported | 06/30/2026 | 1127537614 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,614.08 | 06/14/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD INC | A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1127537628 |
| Principal investigator 1 | PFIZER INC. | $1,705.00 | 06/13/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD INC | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | No dispute reported | 06/30/2026 | 1131068978 |
| Principal investigator 1 | PFIZER INC. | $11,290.56 | 06/11/2024 | Non-covered Recipient Entity Dr Shelly Senders | AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131067086 |
| Principal investigator 1 | PFIZER INC. | $19,390.80 | 06/08/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD INC | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | No dispute reported | 06/30/2026 | 1131065881 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,000.00 | 06/03/2024 | Non-covered Recipient Entity Dr Shelly David Senders Md Inc | Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) | No dispute reported | 06/30/2026 | 1128730638 |
| Principal investigator 1 | PFIZER INC. | $10,602.80 | 05/29/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD INC | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | No dispute reported | 06/30/2026 | 1131081815 |
| Principal investigator 1 | ModernaTX, Inc. | $35,314.03 | 05/24/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147184791 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $207.75 | 05/17/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD INC | A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1127521928 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $217.20 | 05/10/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD INC | A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1127521930 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $830.07 | 05/10/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD INC | A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1127521932 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,051.37 | 05/10/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD INC | A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1127537618 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $217.20 | 05/10/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD INC | A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1127537624 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $217.20 | 05/10/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD INC | A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1127537634 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,381.88 | 05/10/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD INC | A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1127537700 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,051.37 | 05/10/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD INC | A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1127537704 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,704.10 | 05/10/2024 | Non-covered Recipient Entity Dr Shelly David Senders Md Inc | A Multi-center, Multi-national, Prospective Surveillance Study of Respiratory Syncytial Virus Disease in Infants and Toddlers 6 to < 22 Months of Age | No dispute reported | 06/30/2026 | 1128730634 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,000.00 | 05/08/2024 | Non-covered Recipient Entity Dr Shelly David Senders Md Inc | A Multi-center, Multi-national, Prospective Surveillance Study of Respiratory Syncytial Virus Disease in Infants and Toddlers 6 to < 22 Months of Age | No dispute reported | 06/30/2026 | 1128730632 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $181.66 | 05/06/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD INC | A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T | No dispute reported | 06/30/2026 | 1127537710 |
| Principal investigator 1 | PFIZER INC. | $11,665.96 | 05/04/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD INC | A PHASE 1 OPENLABEL AGEDESCENDING DOSEFINDING STUDY AND A PHASE 23 PLACEBOCONTROLLED RANDOMIZED DOUBLEBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE RSVPREF IN CHILDREN 2 TO 18 YEARS OF AGE AT HIGH RISK OF RSV DISEASE | No dispute reported | 06/30/2026 | 1131081556 |
| Principal investigator 1 | PFIZER INC. | $17,854.20 | 05/04/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD INC | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | No dispute reported | 06/30/2026 | 1131081910 |
| Principal investigator 1 | ModernaTX, Inc. | $3.20 | 05/03/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147184795 |
| Principal investigator 1 | ModernaTX, Inc. | $2,470.00 | 05/01/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147184797 |
| Principal investigator 1 | ModernaTX, Inc. | $195.00 | 04/26/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147184767 |
| Principal investigator 1 | PFIZER INC. | $68,117.76 | 04/26/2024 | Non-covered Recipient Entity Dr Shelly Senders | AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131088571 |
| Principal investigator 1 | PFIZER INC. | $85.00 | 04/26/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD INC | A PHASE 1 OPENLABEL AGEDESCENDING DOSEFINDING STUDY AND A PHASE 23 PLACEBOCONTROLLED RANDOMIZED DOUBLEBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE RSVPREF IN CHILDREN 2 TO 18 YEARS OF AGE AT HIGH RISK OF RSV DISEASE | No dispute reported | 06/30/2026 | 1131089154 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $11,482.00 | 04/25/2024 | Non-covered Recipient Entity SENDERS PEDIATRICS | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO | No dispute reported | 06/30/2026 | 1127537608 |
| Principal investigator 1 | ModernaTX, Inc. | $43,970.94 | 04/24/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147184765 |
| Principal investigator 1 | PFIZER INC. | $1,580.00 | 04/19/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD INC | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | No dispute reported | 06/30/2026 | 1131088721 |
| Principal investigator 1 | PFIZER INC. | $3,412.80 | 04/18/2024 | Non-covered Recipient Entity Senders PediatricsResearch | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130900389 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $12,320.83 | 04/15/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD INC | A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1127537702 |
| Principal investigator 1 | PFIZER INC. | $2,419.20 | 04/12/2024 | Non-covered Recipient Entity Senders PediatricsResearch | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | No dispute reported | 06/30/2026 | 1130919056 |
| Principal investigator 1 | PFIZER INC. | $5,760.00 | 04/09/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD INC | A PHASE 1 OPENLABEL AGEDESCENDING DOSEFINDING STUDY AND A PHASE 23 PLACEBOCONTROLLED RANDOMIZED DOUBLEBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE RSVPREF IN CHILDREN 2 TO 18 YEARS OF AGE AT HIGH RISK OF RSV DISEASE | No dispute reported | 06/30/2026 | 1131089160 |
| Principal investigator 1 | PFIZER INC. | $1,359.80 | 04/09/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD INC | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | No dispute reported | 06/30/2026 | 1131089947 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $541.10 | 04/08/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD INC | A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T | No dispute reported | 06/30/2026 | 1127521926 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $730.29 | 04/05/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD INC | A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T | No dispute reported | 06/30/2026 | 1127537626 |
| Principal investigator 1 | PFIZER INC. | $38,904.08 | 04/04/2024 | Non-covered Recipient Entity Dr Shelly Senders | AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131088989 |
| Principal investigator 1 | PFIZER INC. | $11,293.10 | 04/04/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD INC | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | No dispute reported | 06/30/2026 | 1131089375 |
| Principal investigator 1 | ModernaTX, Inc. | $49,166.91 | 04/03/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147184769 |
| Principal investigator 1 | PFIZER INC. | $30,900.00 | 03/30/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD INC | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | No dispute reported | 06/30/2026 | 1131102960 |
| Recipient | ModernaTX, Inc. | $52,454.61 | 03/28/2024 | Covered Recipient Physician | A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease | No dispute reported | 06/30/2026 | 1147190719 |
| Principal investigator 1 | PFIZER INC. | $16,985.54 | 03/27/2024 | Non-covered Recipient Entity Dr Shelly Senders | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131102998 |
| Principal investigator 1 | PFIZER INC. | $2,292.48 | 03/22/2024 | Non-covered Recipient Entity Dr Shelly Senders | AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131103004 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $6,550.00 | 03/20/2024 | Non-covered Recipient Entity Senders Pediatrics | A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants | No dispute reported | 06/30/2026 | 1136404472 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $9,103.66 | 03/15/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD INC | A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1127537616 |
| Principal investigator 1 | PFIZER INC. | $746.20 | 03/08/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD INC | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | No dispute reported | 06/30/2026 | 1131103046 |
| Principal investigator 1 | ModernaTX, Inc. | $45,071.91 | 03/06/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147184761 |
| Principal investigator 1 | PFIZER INC. | $8,809.06 | 03/05/2024 | Non-covered Recipient Entity Dr Shelly Senders | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131102967 |
| Principal investigator 1 | PFIZER INC. | $3,955.90 | 03/01/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD INC | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | No dispute reported | 06/30/2026 | 1131103010 |
| Recipient | ModernaTX, Inc. | $13,500.00 | 02/29/2024 | Covered Recipient Physician | A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease | No dispute reported | 06/30/2026 | 1147190717 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,561.31 | 02/09/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD INC | A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1127537706 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,423.89 | 02/08/2024 | Non-covered Recipient Entity SENDERS PEDIATRICS | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO | No dispute reported | 06/30/2026 | 1127537610 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,670.27 | 02/07/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD INC | A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T | No dispute reported | 06/30/2026 | 1127537632 |
| Principal investigator 1 | ModernaTX, Inc. | $80,065.44 | 02/02/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1147184711 |
| Principal investigator 1 | PFIZER INC. | $7,976.96 | 01/31/2024 | Non-covered Recipient Entity Dr Shelly Senders | AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131109179 |
| Principal investigator 1 | PFIZER INC. | $9,107.80 | 01/26/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD INC | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | No dispute reported | 06/30/2026 | 1131107231 |
| Principal investigator 1 | PFIZER INC. | $6,877.44 | 01/26/2024 | Non-covered Recipient Entity Dr Shelly Senders | AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131107709 |
| Recipient | ModernaTX, Inc. | $33,408.18 | 01/24/2024 | Covered Recipient Physician | A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease | No dispute reported | 06/30/2026 | 1147190713 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,590.91 | 01/17/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD INC | A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1127537622 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $7,646.18 | 01/10/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD INC | A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T | No dispute reported | 06/30/2026 | 1127537708 |
| Principal investigator 1 | ModernaTX, Inc. | $132.48 | 01/09/2024 | Non-covered Recipient Entity DR SHELLY DAVID SENDERS MD | A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease | No dispute reported | 06/30/2026 | 1147185067 |
| Principal investigator 1 | PFIZER INC. | $333.45 | 01/04/2024 | Non-covered Recipient Entity Dr Shelly David Senders MD INC | A PHASE 1 OPENLABEL AGEDESCENDING DOSEFINDING STUDY AND A PHASE 23 PLACEBOCONTROLLED RANDOMIZED DOUBLEBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE RSVPREF IN CHILDREN 2 TO 18 YEARS OF AGE AT HIGH RISK OF RSV DISEASE | No dispute reported | 06/30/2026 | 1131110147 |